ABIVAX press release
Abivax announces the filing of an “Amendment” to the Registration Document (“FORM F-1”), including an indicative price range.
Abivax SA (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on the development of therapeutic treatments that exploit the body’s natural regulatory mechanisms to modulate the immune response in patients suffering from inflammatory diseases chronicles, today announces the formal start of the order book construction procedure and the filing of an “amendment” to the registration document (“Form F-1”), to include a range indicative price in connection with its proposed offering, subject to market and other conditions, of approximately 20,325,500 ordinary shares (including in the form of American Depositary Shares (“ADS”)) of the Company in a public offering, each representing one common share, in the United States (the “US Offering”) and a concurrent offering of common shares in certain countries outside the United States (the “US Offering”). European Private Placement” and, with the US Offer, the “Global Offer”).